Rajesh Patel, MD
Pulmonary Disease · Jackson, MSNPI 1144214925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 759 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by GSK at 24.6% of the total.
Across 759 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Mallinckrodt Hospital Products Inc.$1K
- Mylan Specialty L.p.$926
- Sanofi$837
- plus $3K from 25 others
What the payments were for
- Consulting fees$4003%
- Food & beverage$12,32197%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 222 | $3,127 |
| AstraZeneca | 99 | $1,926 |
| Boehringer Ingelheim | 91 | $1,464 |
| Mallinckrodt Hospital Products Inc. | 78 | $1,394 |
| Mylan Specialty L.p. | 60 | $926 |
| Sanofi | 47 | $837 |
| Bayer | 7 | $477 |
| Regeneron Healthcare Solutions, Inc. | 17 | $322 |
| Grifols USA, LLC | 19 | $283 |
| Mallinckrodt Enterprises LLC | 17 | $257 |
| Genentech USA, Inc. | 8 | $237 |
| Amgen | 10 | $201 |
| United Therapeutics Corporation | 12 | $198 |
| Insmed, Inc. | 18 | $181 |
| Viatris Specialty LLC | 11 | $156 |
| ANI Pharmaceuticals, Inc. | 7 | $126 |
| Philips North America LLC | 6 | $111 |
| Novartis | 6 | $101 |
| Actelion Pharmaceuticals US, Inc. | 5 | $86 |
| Verona Pharma, Inc. | 4 | $75 |
| Merck | 4 | $64 |
| Ambu Inc. | 1 | $31 |
| Johnson & Johnson | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Pulmonx Corporation | 1 | $13 |
| Circassia Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
| Vapotherm Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$400
- Esbriet$125
- TRELEGY ELLIPTA$125
How this compares
$12,736 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 50 | $636,497 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $254,543 |
| XolairOmalizumab | 12 | $66,478 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $65,570 |
| EliquisApixaban | 96 | $63,489 |
| Dupixent PenDupilumab | 13 | $56,689 |
| Breo ElliptaFluticasone/Vilanterol | 85 | $44,182 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $39,243 |
| SymbicortBudesonide/Formoterol Fumarate | 102 | $31,807 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 484 | $24,988 |
| XareltoRivaroxaban | 27 | $21,244 |
| Advair HfaFluticasone Propion/Salmeterol | 44 | $20,110 |
| Spiriva HandihalerTiotropium Bromide | 29 | $18,655 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $14,026 |
| Spiriva RespimatTiotropium Bromide | 23 | $13,677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,464 | $656,20084 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $3,127 | $351,995489 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,926 | $109,828218 claims |
| PfizerEliquis | $12 | $63,48996 claims |
| Johnson & JohnsonXarelto | $30 | $21,24427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- George AbrahamJackson$23K
- Maria RappaiJackson$20K
- Arash SamarghandiJackson$19K
- Kimberly DobbsJackson$14K
- Charles EvansJackson$12K
- Meredith SloanJackson$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.